Literature DB >> 10930644

Retinoic acid reduces the yield of herpes simplex virus in Vero cells and alters the N-glycosylation of viral envelope proteins.

C E Isaacs1, W Xu, R K Pullarkat, R Kascsak.   

Abstract

Treatment of Vero cells with all-trans-retinoic acid (RA) decreased the production of infectious herpes simplex virus (HSV) by 1000-10000-fold when compared with control cultures. Levels of total HSV envelope glycoproteins gB, gC and gD produced following RA treatment, were comparable with those found in control cultures. Following 24 h of RA treatment, lower molecular weight variants of gB, gC and gD were produced in addition to the typical molecular mass of each protein found in control samples. Between 24 and 48 h of RA treatment, the proportion of the lower molecular mass variants increased. When control and RA treated samples were incubated with peptide N-glycosidase F (PNGase F), which removes N-glycosylated sugars, the molecular weights of the respective gB, gC and gD proteins produced were comparable in both the groups, indicating that RA did not alter the primary sequence of viral proteins during protein synthesis or increase viral protein proteolysis. RA treatment increased [3H]mannose incorporation into glycoproteins in HSV infected cells but did not change [3H]glucosamine incorporation. We conclude that RA treatment does not reduce the synthesis of three major viral envelope glycoproteins but alters their N-glycosylation and postulate that the inhibitory effect of RA is related to its action on N-glycosylation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10930644     DOI: 10.1016/s0166-3542(00)00090-5

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  8 in total

1.  Chlamydia pneumoniae uses the mannose 6-phosphate/insulin-like growth factor 2 receptor for infection of endothelial cells.

Authors:  Mirja Puolakkainen; Cho-Chou Kuo; Lee Ann Campbell
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

2.  Herpes simplex virus types 1 and 2 modulate autophagy in SIRC corneal cells.

Authors:  Goran Petrovski; Kata Pasztor; Laszlo Orosz; Reka Albert; Edina Mencel; Morten C Moe; Kai Kaarniranta; Andrea Facsko; Klara Megyeri
Journal:  J Biosci       Date:  2014-09       Impact factor: 1.826

3.  Retinoic acid prevents Chlamydia pneumoniae-induced foam cell development in a mouse model of atherosclerosis.

Authors:  Shinn-Jong Jiang; Lee Ann Campbell; Mark W Berry; Michael E Rosenfeld; Cho-Chou Kuo
Journal:  Microbes Infect       Date:  2008-07-17       Impact factor: 2.700

4.  Retinoic acid inhibits the infectivity and growth of Chlamydia pneumoniae in epithelial and endothelial cells through different receptors.

Authors:  Mirja Puolakkainen; Amy Lee; Tadayoshi Nosaka; Hideto Fukushi; Cho-Chou Kuo; Lee Ann Campbell
Journal:  Microb Pathog       Date:  2007-11-23       Impact factor: 3.738

5.  The Fox and the Rabbits-Environmental Variables and Population Genetics (1) Replication Problems in Association Studies and the Untapped Power of GWAS (2) Vitamin A Deficiency, Herpes Simplex Reactivation and Other Causes of Alzheimer's Disease.

Authors:  C J Carter
Journal:  ISRN Neurol       Date:  2011-07-12

6.  Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation.

Authors:  Soren Gantt; Eliora Gachelet; Jacquelyn Carlsson; Serge Barcy; Corey Casper; Michael Lagunoff
Journal:  Adv Virol       Date:  2015-01-29

Review 7.  Glycosylation of viral proteins: Implication in virus-host interaction and virulence.

Authors:  Tingting Feng; Jinyu Zhang; Zhiqian Chen; Wen Pan; Zhengrong Chen; Yongdong Yan; Jianfeng Dai
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

8.  Proteomics of Bronchoalveolar Lavage Fluid Reveals a Lung Oxidative Stress Response in Murine Herpesvirus-68 Infection.

Authors:  Eric Bortz; Ting-Ting Wu; Parthive Patel; Julian P Whitelegge; Ren Sun
Journal:  Viruses       Date:  2018-11-27       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.